SCHEDULE: Psyence Labs Ltd. Discloses 30.05% Stake in Psyence Biomedical

Psyence Labs Ltd. has filed a Schedule 13D, revealing beneficial ownership of 1,146,159 common shares, representing 30.05% of Psyence Biomedical Ltd., acquired through a share-for-share exchange.

Summary

• Psyence Labs Ltd. has acquired 1,146,159 common shares of Psyence Biomedical Ltd., constituting 30.05% of the outstanding shares.
• The acquisition occurred on February 25, 2026, through a share-for-share exchange valued at US$5,000,000.
• Psyence Labs Ltd. issued 2,900 of its ordinary shares in exchange for the Psyence Biomedical shares.
• The number of Psyence Biomedical shares received was based on its 30-day volume-weighted average price prior to the exchange.
• Psyence Labs Ltd. is a British Virgin Islands company focused on cultivating, manufacturing, and supplying nature-derived psychedelic active pharmaceutical ingredients.
• The acquisition was made for investment purposes, with plans to continuously review the investment and potentially take further actions.
• No cash consideration was exchanged between the parties for the share exchange.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership and investment strategy without immediate positive or negative financial disclosures.

Positives

• Psyence Labs Ltd. has secured a significant 30.05% stake in Psyence Biomedical Ltd., indicating a strong investment position.
• The share exchange was structured without cash, utilizing an existing put option agreement and the issuance of Psyence Labs Ltd. shares.
• The acquisition was completed based on a pre-determined valuation mechanism (30-day VWAP), providing clarity on the exchange terms.

Negatives

• The filing does not explicitly detail any negative financial performance or operational setbacks for either entity.
• The reliance on a put option and share exchange mechanism might suggest a prior financial arrangement or need for capital by Psyence Biomedical.

Risks

• Psyence Labs Ltd. may engage in further transactions, including acquiring additional securities or disposing of existing holdings, which could impact Psyence Biomedical's share price and stability.
• Future actions by Psyence Biomedical's board of directors could influence Psyence Labs Ltd.'s investment strategy.
• Market conditions, general economic factors, and the securities market could affect the value of Psyence Labs Ltd.'s investment.

Future Outlook

Psyence Labs Ltd. intends to continuously review its investment in Psyence Biomedical Ltd. and may, at any time, acquire additional securities, dispose of securities, engage in hedging transactions, or propose other actions related to its investment.

Management Comments

• Psyence Labs Ltd. acquired the Subject Shares for investment purposes.
• The Reporting Person intends to review its investment in the Issuer on a continuing basis and may, from time to time and at any time, depending on various factors, including, without limitation, the Issuer's financial position and strategic direction, actions taken by the Issuer's board of directors (the "Board"), price levels of the Common Shares, conditions in the securities market, and general economic and industry conditions, take such actions with respect to its investment in the Issuer as it deems appropriate.

Industry Context

StockSavvy.ai notes that this filing highlights a significant ownership stake in a company operating within the burgeoning psychedelic pharmaceutical sector. Psyence Labs Ltd.'s business of cultivating and manufacturing psychedelic APIs positions it as a key player in the supply chain for potential therapeutic applications.

Related Party Transactions

• The acquisition of 1,146,159 Common Shares by Psyence Labs Ltd. from Psyence Biomedical Ltd. through a share-for-share exchange, pursuant to a Share Put Option and Amendment Agreement dated July 3, 2025, where Psyence Labs Ltd. issued 2,900 ordinary shares valued at US$5,000,000 in consideration.

Stakeholder Impact

• Shareholders of Psyence Biomedical Ltd. may experience volatility in share price due to potential future transactions by Psyence Labs Ltd.
• The significant stake held by Psyence Labs Ltd. could influence corporate governance decisions and strategic direction of Psyence Biomedical Ltd.

Next Steps

• Psyence Labs Ltd. will continue to monitor its investment in Psyence Biomedical Ltd.
• Psyence Labs Ltd. may take various actions regarding its investment, including acquiring or disposing of securities, or engaging in hedging transactions.

Key Dates

Recommendation

The filing indicates a significant investment by Psyence Labs Ltd. in Psyence Biomedical Ltd., but it primarily reports a change in beneficial ownership and future intentions without providing new financial performance data. The potential for future strategic actions by Psyence Labs Ltd. warrants a 'hold' to observe developments.

Keywords

Psyence Biomedical Ltd., Psyence Labs Ltd., Schedule 13D, Beneficial Ownership, Share Exchange, Investment, Psychedelic Pharmaceuticals, Active Pharmaceutical Ingredients, Ibogaine, Psilocybin